High Expression of Human Uroplakin Ia in Urinary Bladder Transitional Cell Carcinoma

Susumu Kageyama,1 Tatsuhiro Yoshiki,1,3 Takahiro Isono,2 Tsutomu Tanaka,1 Chol Jang Kim,1 Takeshi Yuasa1 and Yusaku Okada1

1Department of Urology and 2Central Research Laboratory, Shiga University of Medical Science, Tsukinowa, Seta, Otsu, Shiga 520-2192

Uroplakins (UPs) Ia, Ib, II, and III are tissue-specific and differentiation-dependent transmembrane proteins of the urothelium. We assessed the usefulness of human UP Ia as a histological marker by examining its expression in urinary bladder transitional cell carcinoma (TCC). A polyclonal antibody against human UP Ia was raised using a synthesized polypeptide. We applied our antibody to various organ tissues, including urothelium, and observed no crossreactivity. Analysis by RT-PCR of normal urothelium, TCC and other organ tissues indicated that the human UP Ia gene expression is highly specialized to urothelium, and is conserved in TCC. Using immunohistochemistry, we investigated the expression of UP Ia in TCC from patients who had undergone radical cystectomy and from autopsy cases. Positive staining (10% or more positive cancer cells) was noted in primary lesions from 61 of 63 (96.8%) cystectomy patients. Depending on pathological grade, high expression (50% or more positive cancer cells) was observed in 17 of 18 (94.4%) moderately- to well-differentiated TCC and in 36 of 45 (80.0%) poorly differentiated TCC. With regard to tumor invasion, high expression was noted in 20 of 22 (90.9%) superficial and 33 of 41 (80.5%) muscle-invasive TCC. Cause-specific survival rates were 68.6% and 75.0% in high- and low-expression patients, respectively (log-rank test, \(P=0.855\), mean follow-up; 65.0 months). In metastases, positive reactions were observed in 13 of 18 (72.2%) lesions. UP Ia may represent a specific histological marker judging from the stable expression, although its value as a prognostic factor remains undetermined.

Key words: Uroplakin Ia — Bladder cancer — Immunohistochemistry

Bladder cancer is a common urological neoplasm in many countries. For example, in the United States and Japan, there are approximately 53 200 and 10 600 newly diagnosed cases per year, respectively.1) Transitional cell carcinoma (TCC) represents the majority (75–90%) of bladder cancer, with squamous cell carcinoma (2–15%), mixed carcinoma (4–6%) and adenocarcinoma (<2%) comprising the remainder of cases.2) Histopathological diagnosis of TCC metastases mainly relies on the morphological features of specimens. When tumors are poorly differentiated or obtained specimens are very small, diagnosis becomes complicated. The establishment of antibodies that react specifically to TCC would be valuable.

Since the 1960’s it has been known that the specific structure of the urothelial apical surface is an asymmetric unit membrane (AUM). However, despite much effort, AUM extraction was not accomplished until 1990, when Yu et al. succeeded in purifying AUM proteins using a monoclonal antibody (AE31) against bovine bladder epithelium plasma membrane.3) They designated these proteins as uroplakins (UPs). Four integral proteins were found, UPs Ia (molecular weight, 27 kDa in non-reduced SDS-PAGE), Ib (28 kDa), II (15 kDa) and III (47 kDa). Immunohistochemical studies revealed that UPs are highly specific for mammalian urothelium; they are present in the apical surface membrane of umbrella cells and are considered as differential antigens. It has been hypothesized that the role of UPs is to protect against bladder wall distention.

Recently, we determined the nucleotide sequences of human UPs Ib and III using PCR-based method.4) We also identified UP gene-expressing cancer cells in the peripheral blood of patients with metastatic TCC by nested RT-PCR and suggested the possibility that UPs might be TCC-specific markers.5–6) Several monoclonal or polyclonal anti-bovine UPs II and III antibodies have been raised, and immunohistochemical studies were performed.7–10) The expression of UPs II and III was observed not only in normal transitional cells, but also in TCC.7–9) However, anti-human UP Ia antibodies have not been produced, nor has UP Ia expression been examined in TCC. Therefore, its clinical usefulness remains unknown.

In the present study, we produced a polyclonal antibody against human UP Ia and assessed its clinical significance by examining expression in TCC specimens.
MATERIALS AND METHODS

Patients Urinary bladder TCC tissues were obtained from 63 patients according to institutional guidelines. All had undergone radical cystectomy and simultaneous bilateral pelvic lymph node dissection at the Department of Urology of Shiga University of Medical Science between 1979 and 1995. Clinical and pathological features are shown in Table I. For statistical analysis, we divided the patients into two categories according to histological grading: those with a well- to moderately-differentiated tumor (18 patients, grades 1–2) and those with a poorly differentiated tumor (45 patients, grade 3). We also divided the patients into two other categories by depth of invasion: superficial tumor (22 patients, Ta-1) and muscle-invasive tumor (41 patients, T2-4). The extent of disease was classified according to TNM staging criteria (4th Ed.). Pelvic lymph node metastases were confirmed pathologically with dissected specimens; 9 patients had lymph node involvement. Fifteen patients underwent cisplatin-based chemotherapy as pre- or post-operative adjuvant therapy. No patient had neoadjuvant irradiation. The follow-up period ranged from 1 to 186 months (mean ± standard deviation [SD] 65.0 ± 48.1 months; median 56). Fifteen of the 63 patients died of disease, and the cumulative cause-specific survival rate was 69.7%.

Eighteen metastatic tissue samples were obtained from 5 patients who had undergone lymph node dissection and 9 autopsy cases who had died of systemically advanced TCC. The sites of metastases were pelvic lymph nodes (n=6), lung (4), liver (4), bone marrow (2), pancreas (1) and colon (1).

Tissues were appropriately processed immediately after surgery or autopsy and embedded in paraffin blocks.

Synthesized polypeptide Based on DNA sequence data of human UP Ia registered in GenBank (Lamerdin, AC002115 and our original data5)), we synthesized a polypeptide corresponding to amino acid residues 141 to 152 (DQGQELTRLWDR). This amino acid sequence is located in the extracellular loop domain and has no similarity to any other sequence in the protein database except that of bovine UP Ia.

Generation of antibody We raised a rabbit polyclonal antibody using the synthetic UP Ia polypeptide as the immunogen. Immunization was performed by injection of keyhole limpet hemocyanin-conjugated polypeptide six times, followed by one booster injection of free polypeptide.

Immunohistochemistry Immunohistochemical staining was performed by the streptavidin-biotin-peroxidase complex method (Histofine SAB-PO(R) kit; Nichirei, Tokyo) as described previously. It should be noted that the specimens were incubated with 0.1% trypsin (Nacalai Tesque, Table I. Patients’ Characteristics and Statistical Analysis of UP Ia Expression in Primary Bladder TCC Tissue and Clinicopathological Features

| Characteristic          | Total (n=63) | UP Ia high-exp. (n=53) | UP Ia low-exp. (n=10) | P value |
|-------------------------|-------------|------------------------|----------------------|---------|
| Age mean (SD)           | 65.1 (9.7)  | 65.6 (9.6)             | 62.5 (10.2)          | 0.358   |
| Sex male                | 51          | 42                     | 9                    | 0.671   |
| female                  | 12          | 11                     | 1                    |         |
| Configuration papillary | 18          | 17                     | 1                    | 0.257   |
| non-papillary           | 45          | 36                     | 9                    |         |
| Number of tumors        |             |                        |                      |         |
| solitary                | 31          | 25                     | 6                    | 0.509   |
| multiple                | 32          | 28                     | 4                    |         |
| Grade well-mod.         | 18          | 17                     | 1                    | 0.257   |
| poor                    | 45          | 36                     | 9                    |         |
| Depth of invasion       |             |                        |                      |         |
| superficial             | 22          | 20                     | 2                    | 0.472   |
| invasive                | 41          | 33                     | 8                    |         |
| Lymph node involvement  |             |                        |                      |         |
| neg.                    | 54          | 46                     | 8                    | 0.626   |
| pos.                    | 9           | 7                      | 2                    |         |
| Lymphatic invasion      |             |                        |                      |         |
| neg.                    | 16          | 13                     | 3                    | 0.705   |
| pos.                    | 33          | 28                     | 5                    |         |
| unknown                 | 14          | 12                     | 2                    |         |
| Venous invasion         |             |                        |                      |         |
| neg.                    | 40          | 34                     | 6                    | 0.628   |
| pos.                    | 9           | 7                      | 2                    |         |
| unknown                 | 14          | 12                     | 2                    |         |
| Follow-up (mo.) mean (SD)| 65.0 (48.1)| 65.2 (47.8)            | 64.3 (52.3)          | 0.957   |
Uroplakin Ia in Bladder Cancer

Inc., Kyoto) in 0.01 M phosphate-buffered saline (PBS) at room temperature for 60 min for the purpose of antigen retrieval after deparaffinization and rehydration. The slides were incubated with anti-UP Ia polyclonal antibody diluted 1:200 at room temperature for 60 min.

To determine organ specificity, our antibody was tested not only on normal bladder tissues, but also on those of various organs (n=27), including the heart, lung, stomach, small intestine, colon, liver, pancreas, spleen, kidney, thyroid, adrenal gland and prostate. To investigate the expression of UP Ia in primary bladder TCC and metastatic lesions, we applied the antibody to specimens according to the above procedure.

RT-PCR  To examine the expression of the UP Ia gene we performed RT-PCR for several tissues. Total RNA was obtained from normal bladder urothelium, TCC tissue of cancer patient and other organ tissues (brain, heart, lung, liver, kidney, appendix, testis, ovary and peripheral blood lymphocytes) of non-TCC patients. Single-strand cDNA was synthesized from 5 µg of total RNA with 20 U of RAV-2 reverse transcriptase (Takara Biochemicals, Kyoto) using random primers. We also synthesized the sense and antisense primers for human UP Ia mRNA as described by Yuasa et al.: 5′-ACGTCTACACCCACCGTGA-3′ and 5′-ACCCCACGTGTAGCTGTCGAT-3′; respectively.5) Sense and antisense primers for GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA were used as controls: 5′-GGATTGGTCTCATTGGCCGCT-3′ and 5′-AGTGAGCTTCCCGTCTAGCTCAG-3′, respectively.13) The PCR reaction included 0.4 µl of template cDNA, 2.5 U of KOD dash polymerase (Toyobo Biochemicals, Osaka), 1 mM MgCl2, 10 mM KCl, 6 mM (NH4)2SO4, 0.1% Triton X-100, 10 µg/ml bovine serum albumin, 0.2 mM each of deoxynucleotide triphosphates and 4 pmol of primers in 20 µl of 120 mM Tris-HCl buffer (pH 8.0). Amplification was performed with 30 cycles of denaturation at 98°C for 10 s, annealing at 55°C for 2 s and elongation at 74°C for 30 s. The PCR products were analyzed by electrophoresis on 2% agarose gel with ethidium bromide.

Immunoblotting  For immunoblotting, we used recombinant human UP Ia, which was produced by the pET System that was developed for expression of recombinant proteins combined with thioredoxin in Escherichia coli based on the T7 promoter-driven system (pET TRX Fusion System 32, Novagen, Darmstadt, Germany). One microgram of the lysate dissolved in sample buffer, including 62.5 mM Tris-HCl, pH 6.8, 5% 2-mercaptoethanol, 2% SDS and 10% glycerol, was loaded onto each lane. Proteins were separated by 18% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions and then transferred onto a polyvinylidene difluoride membrane (Immobilon PVDF; Millipore Co., Bedford, MA) with transfer buffer containing 25 mM tris-base, 192 mM glycine, 0.1% SDS and 10% methanol. The membrane was incubated overnight at 4°C in Super Block in TBS (Pierce, Rockford, IL) to block nonspecific binding sites. Anti-UP Ia antibody (diluted 1:10 000) was incubated with the membrane for 1 h at room temperature. Preimmune serum from the same rabbit was used as a negative control. Peroxidase-labeled antirabbit IgG goat antibody (Vector Laboratories, Inc., Burlingame, CA) diluted 1:10 000 was applied as the second antibody. The immunoproducts were visualized with 3,3′-diaminobenzidine (DAB) and H2O2.

We also performed an absorption test in immunoblot analysis. Recombinant human UP Ia (0.1 and 10 µg) or synthesized polypeptide (10 µg) used as the immunogen was incubated in 100 µl of the anti-UP Ia antiserum

Fig. 1. UP Ia staining in normal transitional cells without nuclear staining. (a) Staining without antigen unmasking. Arrows indicate strong apical membrane in umbrella cells. (b) Staining with antigen retrieval treatment with 0.1% trypsin. Granular stains in the intermediate layer of the epithelium can be seen (arrowheads). ×400.
(diluted 1:50) for 30 min at room temperature, and then further diluted (1:10,000) and applied to the membranes as the first antibody.

**Statistical analysis**  The relationship of the staining reaction to various clinical parameters was analyzed using Student’s t test or Fisher’s exact probability test (2-sided, \( P \) value <0.05). Kaplan-Meier analysis was used to estimate the cumulative cause-specific survival rate, and the log-rank test was employed to assess differences in survival distribution for patients with staining intensity of UP Ia immunohistochemistry. For multivariate analysis, the Cox proportional hazards model was used to examine associa-
tions between potential prognostic factors (histological grade, depth of invasion, tumor configuration, number of tumors, lymph node involvement, perioperative chemotherapy and staining intensity of UP Ia) and survival time. We used StatView version 4.5 (Abacus Concepts, Inc., Berkeley, CA) as statistical software.

RESULTS

Organ specificity of anti-UP Ia polyclonal antibody In the normal bladder, without using the antigen retrieval procedure, slides revealed strong apical membrane staining and weak granular cytoplasmic reactivity in umbrella cells (Fig. 1a). Through the use of antigen-unmasking treatment with 0.1% trypsin, the staining intensity became stronger, and a positive reaction was detected not only in umbrella cells, but also in the intermediate layer of the urothelium (Fig. 1b). The heat-induced epitope retrieval procedure had little effect (data not shown).

All other normal organ tissues \( (n=27) \), including those from the heart, lung, stomach, small intestine, colon, liver, pancreas, spleen, kidney, thyroid, adrenal gland and prostate yielded no reaction. We, therefore, concluded that our polyclonal antibody was specific for urinary transitional cells.

UP Ia expression in transitional cell carcinoma Tissue sections exhibiting immunostaining in 10% or more tumor cells were classified as having “positive expression,” whereas tissue sections with less than 10% of such cells were classified as having “negative expression.” Among primary lesions, UP Ia was detected in 61 of 63 (96.8%) bladders; negative staining was found in only two specimens (Fig. 2a). In most tissues, markedly linear and continuous positive staining was observed in the superficial membrane of the tumor cells (Fig. 2b). Strong granular staining in the cytoplasm and distinct intercellular space were recognized (Fig. 2, c and d). In one patient, many microluminal structures reacted with anti-UP Ia antibody (Fig. 2e). Of 18 metastases 13 (72.2%) showed positive expression of UP Ia (Fig. 3, a–c).

We defined two subgroups for cystectomy specimens according to the intensity of UP Ia immunoreactivity; tis-

Fig. 3. Expression of UP Ia in TCC metastases. (a) Lung metastasis from autopsy. Antiserum reacted to metastatic cancer cells diffusely. (b, c) Lymph node metastases. \( \times200 \).
sue of patients in the “high-expression” group revealed positive staining in 50% or more of the cancer cells while those of the “low-expression” group had either a negative reaction or positive staining in fewer than 50% of the cancer cells. There were 53 (84.1%) and 10 (15.9%) patients in the high- and low-expression groups, respectively.

We also applied our antibody to some urological tumors of histological types other than TCC, but they did not show positive staining (data not shown).

**RT-PCR** In RT-PCR analysis of normal urothelium, TCC and other organ tissues, amplified bands corresponding to the human UP Ia gene were obtained only from normal urothelial and TCC samples. This result indicates that human UP Ia gene expression is highly specialized to urothelium, and is conserved in TCC (Fig. 4).

**Immunoblotting** Immunoblotting with anti-UP Ia antibody revealed a band of approximately 35 kDa, which corresponded to the recombinant human UP Ia (24 kDa in reduced condition) fusion protein with thioredoxin (11 kDa). In the absorption test with recombinant UP Ia and synthesized polypeptide, the 35 kDa band was weakened in intensity or became undetectable. These findings indicated that our antibody specifically recognized epitopes existing in human UP Ia (Fig. 5).

**Relationship between expression of UP Ia and clinicopathological factors in radical cystectomy patients** We sought differences in clinicopathological features and survival rates between the high-UP Ia expression and low-expression groups. Information was obtained from medical records and is summarized in Table I. Age distribution and sex ratio were similar in both groups. Histological grade, depth of invasion, tumor configuration, number of tumors, lymph node involvement and microvessel invasion were not statistically significantly different (P values for each are shown in Table I).

Cause-specific survival rates of UP Ia high-expression cases (alive, 40; cancer deaths, 13) and low-expression cases (alive, 8; cancer deaths, 2) were 68.6% and 75.0%, respectively (Fig. 6). There were no significant differences between groups by the log-rank test (P=0.855). On the other hand, patients with a muscle-invasive tumor (P=0.034) or lymph node involvement (P=0.001) had a sta-
We calculated prognostic factors by means of Cox proportional hazards analysis using histological grade, depth of invasion, tumor configuration, number of tumors, lymph node involvement, perioperative chemotherapy and UP Ia expression intensity (Table II). Lymph node involvement was the only statistically significant prognostic factor, with a hazard ratio of 5.08 (95% confidence interval 1.28–20.41, P=0.021). UP Ia expression intensity did not differ between the two groups.

**DISCUSSION**

Several antibodies reacting to each of the UP proteins have been produced.3, 7, 8, 14–16) However, only a small number of antibodies binding to bovine UP Ia have been reported, and all were generated against bovine UP Ia.3, 14, 15) Therefore, to our knowledge, this is the first report of the establishment of an anti-human UP Ia polyclonal antibody. We chose amino acid residues 141 to 152 (DQGQELTRLWDR) as the immunogen because this sequence is located in the extracellular loop domain and has high specificity for UP Ia. The corresponding amino acid sequence of bovine UP Ia has 83.3% homology and may be preserved in other mammalian urothelium. Wu et al. generated two kinds of anti-bovine UP Ia antisera that responded to amino acid sequences 41 to 59 (VIADQYRIYPLMGVS-GKDD) and 139 to 152 (DNSQGRELTRLWDR).15) They found crossreactivity of their anti-bovine UP Ia antisera to urothelium of eight mammalian species (human, monkey, sheep, pig, dog, rabbit, rat and mouse) by immunoblotting and concluded that the UP structure is highly conserved.

Although we proved that our antibody had no crossreactivity with many human tissues other than urinary transitional cells, we have not yet examined immunoreactions with other mammalian bladders, including bovine bladder.

Concerning tumor tissue other than TCC, Ogawa et al. reported positive staining in ovarian Brenner tumors by immunohistochemical analysis using anti AUM antibody that reacts with all four UPS, and concluded that the Brenner tumor represents urothelial differentiation.10) We could not confirm immunoreactivity in Brenner tumors because of lack of appropriate specimens, but we observed no crossreaction in several tumor specimens of other histological types, including squamous cell carcinoma and adenocarcinoma (data not shown).

We found that the antigen retrieval procedure using trypsin in paraffin sections was effective for immunohistochemistry of UP Ia. Previous reports have described antigen-unmasking treatments including trypsin and microwaves.7, 8, 10, 17–22) We also used a heating method employing a microwave oven, but could not achieve stronger staining than that with untreated slides (data not shown). In our study, the immunoreactivity of the intermediate layer in urothelium was enhanced by the antigen retrieval technique. An electron microscopic study by Wu et al. on the ultrastructural localization of UPS revealed some small vesicles beneath the luminal surface of umbrella cells.23) The vesicles had small patches that reacted with UP antibodies, and they speculated that these patches might have been immature UPS. Antigen retrieval treatment might enhance the immunoreactivity for these immature UPS.

**Table II. Results of Cox Proportional Hazards Analysis**

| Factor                  | Hazard ratio | 95% confidence interval | P value |
|------------------------|--------------|-------------------------|---------|
| Grade                  |              |                         |         |
| well-mod.              | 1            | 0.73–2.69               | 0.638   |
| poor                   | 2.83         | 0.54–14.85              | 0.218   |
| Depth of invasion      |              |                         |         |
| superficial            | 1            | 1.52–14.85              | 0.224   |
| invasive               | 2.7          | 0.55–13.35              |         |
| Configuration          |              |                         |         |
| papillary              | 1            | 0.41–3.61               | 0.731   |
| non-papillary          | 1.21         |                         |         |
| Number of tumors       |              |                         |         |
| solitary               | 1.22         | 0.30–5.02               | 0.780   |
| multiple               | 1.69         | 0.32–9.01               | 0.536   |
| Lymph node involvement |              |                         |         |
| neg.                   | 1            |                         |         |
| pos.                   | 5.08         | 1.28–20.41              | 0.021   |
| Perioperative chemotherapy |          |                         |         |
| no                     | 1            |                         |         |
| yes                    | 1.22         | 0.30–5.02               | 0.780   |
| UP Ia expression       |              |                         |         |
| low                    | 1            |                         |         |
| high                   | 1.69         | 0.32–9.01               | 0.536   |

Statistically significantly poorer outcome than those without such factors.

Table II: Results of Cox Proportional Hazards Analysis
ing in primary cancer lesions was detected in 61 of 63 (96.8%) patients. This positive rate was much higher than formerly reported for UPs II and III. Using anti UP II antibodies, Wu et al. reported that UP II was detected in 17 of 43 (39.5%) bladder TCCs. Moll et al. and Kaufmann et al. detected UP III in 43 of 71 (61%) and 21 of 35 (60%) bladder TCCs, respectively. Therefore, UP Ia might be superior to UPs II or III as a histological marker.

UPs were thought to be more frequently detected in well-differentiated than in poorly differentiated TCC as a result of their upregulation upon urothelial differentiation. Moll et al. reported positive reactions for UP III in 14 of the 16 (88%) papillary non-invasive TCCs that they examined, which included many differentiated tumors, and 29 of 55 (53%) invasive TCCs, which included a large proportion of high-grade tumors. However, Kaufmann et al. reported no difference in positive staining rates for UP III between grade 2 (6 of 11, 54%) and grade 3 (15 of 24, 62%) primary bladder tumors. In our study, we also obtained a greater high-expression rate in well- to moderately-differentiated tumors (17 of 18, 94.4%) than in poorly differentiated tumors (36 of 45, 80.0%), but the difference was not statistically significant (P=0.257). The relationship between the expression of UPs and tumor histological grade remains uncertain.

Our antibody was able to identify cancer cell foci in metastatic lesions; the detection rate was 72.2% (13 of 18 metastases). At present, pathologists base their diagnosis mainly upon the morphological features of TCC metastases and have no helpful antibodies to specify tissues of origin. Our RT-PCR analysis revealed no mRNA expression of the UP Ia gene in other organs except normal and malignant transitional cells. This antibody, therefore, may become a powerful tool for identifying metastatic cells of uncertain origin.

Expression of UP Ia was not useful as a prognostic factor. In cause-specific survival analysis, there was no statistically significant difference in UP Ia expression in primary lesions according to the log-rank test and Cox proportional hazards model. Unfortunately, the usefulness of UP Ia as a prognostic factor could not be demonstrated. We speculate that UPs are so highly conserved in TCC as differential products that we could not distinguish between good- and poor-outcome populations. A study employing a larger number of subjects will be required to clarify this issue.

There are at least two interesting possibilities for exploiting our antibody in clinical practice. The first is as a histodiagnostic tool for cancer metastases of uncertain origin, as mentioned above. The second is as an assay system for detection of TCC. The quantity of UP Ia, as well as BLCA-4, in urine may increase in TCC cases owing to the rapid disruption of cancer cells. For urologists and oncologists, whether TCC patients have tumor cells after local (transurethral resection, radical cystectomy, irradiation, and bladder instillation therapy) or systemic treatment is an important issue. We have already proved the existence of TCC cells in peripheral blood using RT-PCR for UPs. If an assay for detecting epitopes of UPs in blood or urine is further developed, it may become a very informative clinical test for screening and surveillance of TCC.

ACKNOWLEDGMENTS

The authors thank Dr. Etsuro Hashimura (Otsuka Pharmaceutical Co., Ltd.) for technical support, and Dr. Takahiro Kawakami (Department of Urology, Shiga University of Medical Science) for providing clinical materials. This study was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan, the Suzuki Foundation for Urological Medicine, and the Japanese Foundation for Multidisciplinary Treatment of Cancer.

(Received November 29, 2001/Revised February 13, 2002/Accepted February 21, 2002)
blood of patients with urothelial cancer. *Clin. Cancer Res.*, 6, 3166–3171 (2000).
7) Moll, R., Wu, X.-R., Lin, J.-H. and Sun, T.-T. Uroplakins, specific membrane proteins of urothelial umbrella cells, as histological markers of metastatic transitional cell carcinomas. *Am. J. Pathol.*, 147, 1383–1397 (1995).
8) Kaufmann, O., Volmerig, J. and Manfred, D. Uroplakin III is a highly specific and moderately sensitive immunohistochemical marker for primary and metastatic urothelial carcinomas. *Am. J. Clin. Pathol.*, 113, 683–687 (2000).
9) Wu, R.-L., Osman, I., Wu, X.-R., Lu, M.-L., Zhang, Z.-F., Liang, F.-X., Hamza, R., Scher, H., Cordon-Cardo, C. and Sun, T.-T. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma; alternative pathways of bladder epithelial differentiation and tumor formation. *Cancer Res.*, 58, 1291–1297 (1998).
10) Ogawa, K., Johansson, S. L. and Cohen, S. M. Immunohistochemical analysis of uroplakins, urothelial specific proteins, in ovarian Brenner tumors, normal tissues, and benign and neoplastic lesions of the female genital tract. *Am. J. Pathol.*, 155, 1047–1050 (1999).
11) Kageyama, S., Yoshiki, T., Hamaguchi, A., Konishi, T., Okada, Y., Park, K.-I. and Tomoyoshi, T. Clinical analysis of bladder cancer patients treated by radical cystectomy. *Acta Urol. Jpn.*, 43, 1–6 (1997) (in Japanese).
12) Hermanek, P. and Sobin, L. H., ed. “UlICC-International Union against Cancer TNM Classification of Malignant Tumours,” 4th Ed., pp. 135 (1987). Springer-Verlag, Heidelberg.
13) Tanaka, T., Yoshiki, T., Araig, Y., Higuchi, K., Kageyama, S., Ogawa, Y., Isono, T. and Okada, Y. Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human bladder cancer. *Jpn. J. Cancer Res.*, 90, 1344–1350 (1999).
14) Yu, J., Lin, J.-H., Wu, X.-R. and Sun, T.-T. Uroplakins Ia and Ib, two major differentiation products of bladder epithelium, belong to a family of four transmembrane domain (4TM) proteins. *J. Cell Biol.*, 125, 171–182 (1994).
15) Wu, X.-R., Lin, J.-H., Walz, T., Härner, M., Yu, J., Aebi, U. and Sun, T.-T. Mammalian uroplakins. A group of highly conserved urothelial differentiation-related membrane proteins. *J. Biol. Chem.*, 269, 13716–13724 (1994).
16) Adachi, W., Okubo, K. and Kinoshita, S. Human uroplakin Ib in ocular surface epithelium. *Invest. Ophthalmol. Vis. Sci.*, 41, 2900–2905 (2000).
17) Schaefer, B. M., Lorenz, C., Back, W., Moll, R., Sun, T.-T., Schober, C., Waag, K. L. and Kramer, M. D. Autologous transplantation of urothelium into demucosalized gastrointestinal segments: evidence for epithelialization and differentiation of *in vitro* expanded and transplanted urothelial cells. *J. Urol.*, 159, 284–290 (1998).
18) Zhang, Z.-T., Pak, J., Shapiro, E., Sun, T.-T. and Wu, X.-R. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma *in situ* and invasive transitional cell carcinoma. *Cancer Res.*, 59, 3512–3517 (1999).
19) Gitlin, J. S., Wu, X.-R., Sun, T.-T., Ritchey, M. L. and Shapiro, E. New concepts of histological changes in experimental augmentation cystoplasty: insights into the development of neoplastic transformation at the entero vesical and gastro vesical anastomosis. *J. Urol.*, 162, 1096–1100 (1999).
20) Ogawa, K., St John, M., Luiza de Oliveira, M., Arnold, L., Shirai, T., Sun, T.-T. and Cohen, S. M. Comparison of uroplakin expression during urothelial carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats and mice. *Toxicol. Pathol.*, 27, 645–651 (1999).
21) Malagolini, N., Cavallone, D., Wu, X.-R. and Serafini-Cessi, F. Terminal glycosylation of bovine uroplakin III, one of the major integral-membrane glycoproteins of mammalian bladder. *Biochim. Biophys. Acta.*, 1475, 231–237 (2000).
22) Shapiro, E., Huang, H.-Y. and Wu, X.-R. Uroplakin and androgen receptor expression in the human fetal genital tract: insights into the development of the vagina. *J. Urol.*, 164, 1048–1051 (2000).
23) Wu, X.-R., Manabe, M., Yu, J. and Sun, T.-T. Large scale purification and immunocalization of bovine uroplakins I, II, and III. Molecular markers of urothelial differentiation. *J. Biol. Chem.*, 265, 19170–19179 (1990).
24) Lobban, E. D., Smith, B. A., Hall, G. D., Harnden, P., Roberts, P., Selby, P. J., Trejosiewicz, L. K. and Southgate, J. Uroplakin gene expression by normal and neoplastic human urothelium. *Am. J. Pathol.*, 153, 1957–1967 (1998).
25) Koney, B. R., Nguyen, T. S., Dhir, R., Day, R. S., Becich, M. J., Stadler, W. M. and Getzenberg, R. H. Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4. *Clin. Cancer Res.*, 6, 2618–2625 (2000).